

Electronic Supplementary Information

A monofunctional Pt(II) complex combats triple negative breast cancer by engaging lysosome-dependent cell death

Xiaomin Shen,^a Yue Peng,^a Zidong Yang,^a Renhao Li,^a Haixia Zhou,^c Xiaoxia Ye,^{*a} Zhong Han,^{*b} and Xiangchao Shi^{*a}




Fig. S1 ¹H NMR spectrum (400 MHz, CDCl₃) of compound 1.




Fig. S2 ¹³C NMR spectrum (100 MHz, CDCl₃) of compound 1.




Fig. S3 ESI mass spectrum of compound 1.




Fig. S4 ¹H NMR spectrum (400 MHz, CDCl₃) of compound 2.




Fig. S5 ¹³C NMR spectrum (100 MHz, CDCl₃) of compound 2.




Fig. S6 ESI mass spectrum of compound 2.




Fig. S7 ¹H NMR spectrum (400 MHz, CDCl₃) of ligand L.




Fig. S8 ¹³C NMR spectrum (100 MHz, CDCl₃) of ligand L.




Fig. S9 ESI mass spectrum of ligand L.




Fig. S10 ^1H NMR spectrum (400 MHz, methanol- d_4) of complex PtL.




Fig. S11 ^{13}C NMR spectrum (100 MHz, methanol- d_4) of complex PtL.




Fig. S12 High resolution mass spectrum of complex PtL.




Fig. S13 Analytical HPLC trace for PtL, the gradient (0.05% TFA in water/MeCN) runs from 90:10 to 0:100, flow rate: 1 mL/min, retention time: 8.972 mins.